117 related articles for article (PubMed ID: 1173058)
1. Clincal pharmacology of O2,2'-cyclocytidine.
Rodriguez DH; Loo TL; Bodey GP; Freireich EJ
Clin Pharmacol Ther; 1975 Jan; 17(1):66-72. PubMed ID: 1173058
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs.
Ho DH; Carter CJ; Loo TL; Abbott RL; McBride CM
Drug Metab Dispos; 1975; 3(4):309-13. PubMed ID: 240662
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Yamada K; Kawashima K; Kato Y; Morishima Y; Tanimoto M; Ohno R
Recent Results Cancer Res; 1980; 70():219-29. PubMed ID: 6766563
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system.
Ho DH; Brown NS; Benvenuto J; McCredie KB; Buckels D; Freireich EJ
Clin Pharmacol Ther; 1977 Sep; 22(3):371-4. PubMed ID: 268246
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
Nakamura T; Ueda T
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
[TBL] [Abstract][Full Text] [Related]
6. ARA-C analogs.
Alberto P
Antibiot Chemother (1971); 1978; 23():88-98. PubMed ID: 348088
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
8. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
Rahman YE; Patel KR; Cerny EA; Maccoss M
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
Ueda T; Nakamura T; Kagawa D; Uchida M; Domae N; Sugiyama M; Ueda Y; Sasada M; Uchino H
Cancer Chemother Pharmacol; 1989; 24(6):371-5. PubMed ID: 2791191
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
12. Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
Kreis W; Gordon CS; DeJager R; Krakoff IH
Cancer Res; 1975 Sep; 35(9):2453-60. PubMed ID: 1149046
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
Ho DH; Neil GL
Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
[TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
[TBL] [Abstract][Full Text] [Related]
16. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
18. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
[TBL] [Abstract][Full Text] [Related]
19. Physiologic disposition of cytosine arabinoside and its derivatives in man.
Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
[TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
